The potential utility of CYGB promoter methylation as a molecular biomarker in NSCLC (Shivapurkar et al, 2008) and HNSCC (Shaw et al, 2007) has also been explored. The gene discussed is CYGB; the disease is head and neck squamous cell carcinoma.